Ailanthone

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Medical and Health Science and Technology Development Project of Shandong Province and 2 more

Animals1

Outcomes

Osteoclast differentiation

downin mouse cells1

1 study

Ailanthone inhibits osteoclast differentiation in mouse cells.
“AIL, that can significantly inhibit osteoclastogenesis linked to inflammaging”
Cells
Ailanthone hijacks ERK/NF-κB cascade to attenuate osteoclastogenesis for osteoporosis
Phytomedicine : international journal of phytotherapy and phytopharmacology22 Jan 2026

MAPK/ERK signalling

downin mouse cells1

1 study

Ailanthone inhibits MAPK/ERK signalling in mouse cells.
“AIL blocks ERK1/2 phosphorylation, thereby influencing the NF-κB signaling cascade.”
Cells
Ailanthone hijacks ERK/NF-κB cascade to attenuate osteoclastogenesis for osteoporosis
Phytomedicine : international journal of phytotherapy and phytopharmacology22 Jan 2026

Latest

1 in 12 months

Phytomedicine5 Feb

Ailanthone hijacks ERK/NF-κB cascade to attenuate osteoclastogenesis for osteoporosis

Experiments in miceOsteoporosis

Paper

Ailanthone

Outcomes

Latest

Ailanthone hijacks ERK/NF-κB cascade to attenuate osteoclastogenesis for osteoporosis

Related